Immunogenicity and Safety of Multiple Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adult and Elderly Subjects

Sanofi15 个研究点分布在 1 个国家目标入组 548 人开始时间: 2009年10月1日最近更新: 2011年10月3日

适应症

干预措施

试验速览

阶段: 2 期
状态: 已完成
发起方: Sanofi
入组人数: 548
试验地点: 15
主要终点: Number of Participants With Detectable Antibodies Before and Following Vaccination With Either Adjuvanted or Non-adjuvanted A/H1N1 Pandemic Vaccine or a Placebo: Age 18 to 64 Years

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The purpose of the study is to evaluate different doses of the Influenza A/H1N1 pandemic vaccine in adults and the elderly.

Primary Objectives:

To describe the immunogenicity of the candidate vaccines after a single injection.
To describe the safety of the candidate vaccines after a single injection.

详细描述

Participants will receive a single injection of their randomized vaccine on Day 0.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Prevention
盲法: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 是

入选标准

•Healthy adults aged 18 years or older on the day of inclusion
•Informed consent has been signed and dated
•Able to attend all scheduled visits and comply with all trial procedures
•For a woman of child-bearing potential, use of an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination, until at least 4 weeks after last vaccination.

排除标准

•Known pregnancy or positive urine pregnancy test
•Currently breastfeeding a child
•Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination
•Planned participation in another clinical trial during the present trial period
•Receipt of any vaccine in the 4 weeks preceding the trial vaccination, except for the inactivated seasonal influenza vaccine, within two weeks preceding trial vaccination
•Planned receipt of any vaccine prior to the Day 42 blood sample
•Receipt of blood or blood-derived products in the past 3 months which might interfere with the assessment of immune response
•Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
•Self-reported seropositivity for Human Immunodeficiency Virus (HIV), Hepatitis B antigen, or Hepatitis C
•Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine(s) used in the trial or to a vaccine containing any of the same substances
•Self reported thrombocytopenia contraindicating intramuscular (IM) vaccination
•Bleeding disorder or receipt of anticoagulants in the 3 weeks preceding inclusion contraindicating IM vaccination
•Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily
•Current alcohol abuse or drug addiction that may interfere with the subject's ability to comply with trial procedures
•Chronic illness that in the opinion of the Investigator, is at a stage where it might interfere with trial conduct or completion
•Employees of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as family members of the employees or the Investigator
•Previous participation in a swine-origin A/H1N1 pandemic flu trial except if performed in 1976
•Any confirmed case of influenza (including swine-origin A/H1N1 Influenza) since March 2009
•Febrile illness (temperature ≥ 100.4°F [≥ 38.0°C ]) or moderate or severe acute illness/infection (according to Investigator judgment) on the day of vaccination
•Personal or family history of Guillain-Barré syndrome
•Active neoplastic disease or a history of any hematologic malignancy
•Known seizure/epilepsy history and/or taking anti-seizure medication
•Receipt of psychiatric drugs. Subjects receiving a single antidepressant drug and stable for at least 3 months prior to enrollment, without decompensating symptoms will be allowed to enroll in the study
•Any Grade 1, 2, or 3 liver function values (Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), and Alkaline phosphatase) observed in blood sample taken at Screening
•Any Grade 2 or Grade 3 laboratory abnormalities in blood sample taken at Screening
•Receipt of any monovalent 2009 pandemic H1N1 vaccine.

研究组 & 干预措施

A/H1N1 Vaccine Group 1

Experimental

Participants will receive A/H1N1 vaccine formulation 1 (with adjuvant)

干预措施: Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant (Biological)

A/H1N1 Vaccine Group 2

Experimental

Participants will receive A/H1N1 vaccine formulation 2 (with adjuvant)

干预措施: Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant (Biological)

A/H1N1 Vaccine Group 3

Active Comparator

Participants will receive A/H1N1 vaccine formulation 3

干预措施: Monovalent Subvirion A/H1N1 influenza vaccine (Biological)

A/H1N1 Vaccine Group 4

Active Comparator

Participants will receive A/H1N1 vaccine formulation 4

干预措施: Monovalent Subvirion A/H1N1 influenza vaccine (Biological)

Placebo Group 5

Placebo Comparator

Participants will receive a placebo vaccine

干预措施: Normal saline solution (Biological)

结局指标

主要结局

Number of Participants With Detectable Antibodies Before and Following Vaccination With Either Adjuvanted or Non-adjuvanted A/H1N1 Pandemic Vaccine or a Placebo: Age 18 to 64 Years